dromlakhani Consider testosterone therapy after radical prostatectomy with undetectable PSA and favorable pathology
STEP 1 — Gather Information
Collect postoperative PSA value (preferably <0.01 ng/mL), pathology report assessing surgical margins, seminal vesicle involvement, and lymph node status; document symptoms of hypogonadism (low libido, fatigue, ED); obtain two morning fasting total testosterone measurements (<12 nmol/L); ensure no evidence of biochemical recurrence or active disease.
STEP 2 — Rule In / Rule Out
If PSA is undetectable and pathology shows negative margins, negative seminal vesicles, and negative lymph nodes → proceed to Step 3; otherwise → do not offer testosterone therapy and evaluate for other causes of hypogonadism or consider oncology referral.
STEP 3 — Classify or Stratify
Classify the patient as a low‑risk candidate for testosterone therapy when criteria in Step 2 are met; if any pathology feature is positive (margins, SV, nodes) or PSA detectable, defer testosterone therapy and obtain multidisciplinary input before reconsideration.
STEP 4 — Decide
Initiate testosterone therapy after shared decision‑making, targeting a mid‑normal total testosterone range; obtain baseline PSA and digital rectal examination, then follow monitoring schedule per Table4 (symptoms, adverse events, testosterone, hematocrit, PSA, DRE at baseline, 3 mo, 6 mo, and yearly).
Clinical Guardrails / Mimics / Pitfalls
Do not offer testosterone therapy if PSA is detectable, margins are positive, seminal vesicles or nodes are involved, or if there is any suspicion of biochemical recurrence; avoid monotherapy for erectile dysfunction without confirmed hypogonadism; never omit baseline PSA/DRE or ongoing prostate cancer surveillance; do not ignore patient preferences or fail to discuss potential risks of theoretical prostate cancer stimulation.
Concrete Clinical Example
A 62‑year‑old man 3 months post‑radical prostatectomy for Gleason 3+4 prostate cancer presents with fatigue and decreased libido. His PSA is <0.01 ng/mL, pathology shows negative margins, negative seminal vesicles, and negative lymph nodes. Total testosterone is 8 nmol/L on two morning samples. After discussing risks and benefits, testosterone therapy is started with plans for PSA and DRE monitoring every 3 months initially.
Source: Male hypogonadism: recommendations from the Fifth International Consultation on Sexual Medicine (ICSM 2024), Mohit Khera et al., Sexual Medicine Reviews, 2025, 13:548-573, https://doi.org/10.1093/sxmrev/qeaf036